A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors Abstract #1505

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Aim(s): Assess the effectiveness of the NETest as a PRRT predictive marker.
Materials and methods: 177Lu-octreotate treated NETs (n=54) followed for 33 months. Histological grade, somatostatin receptor imaging (SRI), CgA (ELISA, normal<108ng/ml) and NETest (qPCR with multianalyte algorithmic analyses) were evaluated. A mathematical response index comprising NETest genes regulating metabolism and growth factor signaling and grade was developed as a Predictive Quotient Index (PQI). Response was assessed by RECIST.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Keywords: NETest, PRRT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1190 Blood Gene Transcript Analysis Predicts 68Ga- SSA-PET/CT Imaging in Neuroendocrine Tumors and Defines Disease Status
Introduction: Limitations of biomarkers and imaging are a concern in the identification of NET status and therapy response.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Kidd M, Modlin I, Drozdov I, ...
#1228 Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy
Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Paganelli G, Kidd M, Severi S, ...
#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs
Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Bodei L, Severi S, Drozdov I, ...
#1916 Circulating Neuroendocrine Transcripts and Gene Cluster Analysis Predict the Efficacy of PRRT
Introduction: Prediction of PRRT efficacy is critical. We tested a blood-based multigene NET transcript analysis (NETest) to predict efficacy in 2 PRRT-treated NET cohorts. The algorithm comprises >50 genes + clusters of growth factor signaling (GFS) and metabolism (MTB).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Lisa Bodei
Authors: Bodei L, Kidd M, Singh A, Severi S, ...
Keywords: PRRT, efficacy
#2216 Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker
Introduction: We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Professor Mark Kidd